Sinocare Inc
SZSE:300298

Watchlist Manager
Sinocare Inc Logo
Sinocare Inc
SZSE:300298
Watchlist
Price: 23.29 CNY -5.56% Market Closed
Market Cap: 12.9B CNY
Have any thoughts about
Sinocare Inc?
Write Note

Sinocare Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sinocare Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sinocare Inc
SZSE:300298
Cash & Cash Equivalents
ÂĄ669.6m
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
2%
A
APT Medical Inc
SSE:688617
Cash & Cash Equivalents
ÂĄ1.3B
CAGR 3-Years
120%
CAGR 5-Years
70%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cash & Cash Equivalents
ÂĄ6.5B
CAGR 3-Years
35%
CAGR 5-Years
57%
CAGR 10-Years
36%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cash & Cash Equivalents
ÂĄ20.5B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Cash & Cash Equivalents
ÂĄ1.7B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cash & Cash Equivalents
ÂĄ7.5B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sinocare Inc
Glance View

Market Cap
13.1B CNY
Industry
Health Care

Sinocare, Inc. engages in the research, development, manufacture, and commercialization of biosensor-based blood glucose monitoring systems. The company is headquartered in Changsha, Hunan and currently employs 3,534 full-time employees. The company went IPO on 2012-03-19. The firm mainly provides micro blood instant blood sugar monitoring systems including blood sugar testing instruments and related blood sugar testing strips, as well as blood sugar testing systems and mobile blood sugar instruments, among others. The firm also provides diabetes management information systems. The company distributes its products within domestic market and to overseas markets under the brand name of SANNUO.

Intrinsic Value
36.62 CNY
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Sinocare Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
669.6m CNY

Based on the financial report for Jun 30, 2024, Sinocare Inc's Cash & Cash Equivalents amounts to 669.6m CNY.

What is Sinocare Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%

Over the last year, the Cash & Cash Equivalents growth was -32%. The average annual Cash & Cash Equivalents growth rates for Sinocare Inc have been 4% over the past three years , 2% over the past five years , and 2% over the past ten years .

Back to Top